The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...
Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback